JKJeevan Kumar

Jeevan Kumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeevan Kumar has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real World Data on Solitary Plasmacytoma From Eastern India- Highlighting Favorable Trends in Outcome

    by Dibakar Podder, Himadri Sonowal, Saswata Saha, Bikash Shah, Shouriyo Ghosh, Jeevan Kumar, Arijit Nag, Debranjani Chattyopadhyay, Rizwan Javed, Asish Rath, et al.

  • Open Access

    Real world data on Solitary Plasmacytoma from eastern India- highlighting favorable trends in outcome

    by Dibakar Podder, Himadri Sonowal, Saswata Saha, Bikash Shah, Shouriyo Ghosh, Jeevan Kumar, Arijit Nag, Debranjani Chattyopadhyay, Rizwan Javed, Ashish Rath, et al.

    Introduction: Solitary plasmacytomas (SP) are rare neoplasm of localised proliferation of clonal plasma cells. It can be classified based on site of involvement and bone marrow involvement. It is an indolent disease in the majority of patients. Primary modality of treatment is radiotherapy and surgical excision. Materials and methods: This was a retrospective audit of SP who were treated and followed up at a tertiary care center in eastern India from January 2012 to December 2025. Patients who has solitary plasma cytoma with more than 10% plasma cells, POEMS syndrome, have been excluded from analysis. Results: We identified 46 patients of SP. The median age of the studied population was 53 years (23-75 years). Males were more commonly affected than females (M:F=2.2:1). Most common chief complaints were bony pain (67.4%). SBP was seen in 39 (84.8%) cases whereas SEP was seen in 7 (15.2%) cases. Vertebra was the most common site of involvement (61.4%). Median M band concentration 0.24 g/dL (0.1 to 1.95 gm/dL). IgG was the most common isotype accounting for 60.6% cases. Six cases (13%) had minimal bone marrow involvement. The majority of the patients received local radiotherapy (89.1%). With a median follow up of 5.4 years (95% CI: 1.8 – 9.0), median OS was not reached, median PFS was 9.22 years (95% CI: 5.8-12.6), median time to next treatment (TTNT) was 9.86 years (95% CI: 6.8 – 12.9). Conclusion: Solitary plasmacytoma commonly affects young males. Bones are more commonly affected than extramedullary sites. SP has a lower rate of progression and excellent prognosis when treated with local radiotherapy.

  • End-of-induction MRD predicts early survival in high-risk adult B-acute lymphoblastic leukemia: A study from Eastern India

    by Prakhar Gupta, Meghna Tyagi, Subhajit Brahma, Shouriyo Ghosh, Dibakar Podder, Debranjani Chattopadhyay, Jeevan Kumar, Arijit Nag, Reena Nair, Asish Rath, et al.


  • Ponatinib in Chronic Myeloid Leukaemia Refractory To Multiple Tyrosine Kinase Inhibitors: Data from a Tertiary Care Centre in India

    by Baalamurugan. K. T, Shouriyo Ghosh, Dibakar Podder, Sharthak Ghosh, Manik Ghosh, Arijit Nag, Debranjani Chattopadhyay, Jeevan Kumar, Rizwan Javed, Saswata Saha, et al.

  • Unusual Blast Phase Transformations in Chronic Myeloid Leukemia: A Case Series Highlighting the Diagnostic Value of Integrated Immunophenotyping

    by Meghna Tyagi, Manasvi Shah, Avik Basu, Jeevan Kumar, Arijit Nag, Reena Nair, Asish Rath, Sushant Vinarkar, Mayur Parihar, Deepak Kumar Mishra

    Blast phase (BP) transformation in chronic myeloid leukemia (CML) represents a progression to an aggressive clinical state with dismal outcomes. While most cases exhibit myeloid lineage, rare transformations to megakaryoblastic, mixed phenotype, or undifferentiated forms pose significant diagnostic and therapeutic challenges. In this case series we describe the clinicopathological, immunophenotypic, and molecular features of three rare CML-BP cases and emphasize the role of integrated diagnostics in identifying atypical blast phenotypes. Three adult CML patients presenting in BP were evaluated using peripheral smear morphology, bone marrow examination, immunohistochemistry, multiparameter flow cytometry, and molecular analysis for BCR::ABL1 transcript variants. The first case demonstrated megakaryoblastic transformation with CD41/CD61 positivity. The second case presented as acute undifferentiated leukemia, with blasts lacking definitive lineage markers. The third case exhibited a mixed B/monocytic phenotype consistent with MPAL-B/M, confirmed by dual-lineage antigen expression. All cases expressed the p210 BCR::ABL1 transcript, supporting a diagnosis of CMLrelated secondary blast crisis. Outcomes varied, with one patient achieving molecular remission post-transplant, while others experienced treatment-related complications or succumbed to disease. Atypical phenotypes in CML-BP require a high index of suspicion. Timely integration of flowcytometry and molecular diagnostics is critical to distinguish secondary blast transformation from de novo leukemia and to guide appropriate management strategies.

  • A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India

    by Durba Biswas, Debapriya Basu, Arijit Nag, Jeevan Kumar, Suvro Sankha Datta

    The aim of this study is to analyze the profile of patients receiving daratumumab and their presentation to the transfusion laboratory by looking at the different pre-transfusion policies and the risk of erythrocyte alloimmunization. Patients receiving daratumumab from 2018 to 2023 were reviewed. They were divided into two groups: Group I, presented before administration of daratumumab, and Group II, presented after drug administration. Appropriate strategies were applied to mitigate the drug interference, and the transfusion outcome was analyzed by following up with the patients for six months. A total of 48 patients were studied. The antibody screen was negative in patients who presented before the administration of daratumumab (n = 35). Extended phenotyping was done for 31 patients. Blood group genotyping was done for 4 patients. The patients who presented after daratumumab administration (n = 13) had a positive antibody screen that became negative with dithiothreitol-treated cells. A total of 261 red cell units were transfused to these patients (mean 5.55 units per patient). None of the patients developed antibodies during the follow-up period. The transfusion services must frame policies and protocols to mitigate drug interference. Good communication between transfusion services and clinical hematologists is a must to ensure safe transfusions.